drugset / Trial / NCT04619433
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of SHR-1210 in combination with Famitinib plus chemotherapy in subjects with NSCLC.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2025-08-16
- Completion
- 2025-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | — | — |
| Subject | Famitinib | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |